Helena Kopp Kallner

Learn More
By B. MODAN, B. PADEH, H. KALLNER, E. Axsr IN, D. MEYTES, P. CZERNIAK, B. RAMOT, J. PINKHAS AND M. MODAN T HE RELATIVELY HICH RISK of developing leukemia in the course of polycythemia vera ( PV ) , and the presence of both specific and nonspecific chromosomal aberrations in patients with myeloprohferative disorders,25 led us to undertake a prospective(More)
OBJECTIVES The aim of this study was to evaluate the diagnostic accuracy of sensitivity and specificity of cervical lesions by the low-cost, portable Gynocular colposcope and a stationary colposcope, in women referred for colposcopy with abnormal cervical cytology. METHODS A randomized cross-over clinical trial for evaluating the diagnostic accuracy in(More)
OBJECTIVE To determine risks associated with prescribing mirabegron, the first-in-class β3-adrenoreceptor agonist, to non-selected female patients with overactive bladder. STUDY DESIGN Routine female patients seeking treatment for overactive bladder (n=221) in a urology/gynecology outpatient clinic. Data on adverse events, cardiovascular outcomes,(More)
OBJECTIVE To evaluate the cost-effectiveness of a novel intrauterine system, levonorgestrel intrauterine system 13.5 mg vs. oral contraception, in women at risk of unintended pregnancy. DESIGN Cost-effectiveness model using efficacy and discontinuation data from published articles. SETTING Societal perspective including direct and indirect costs. (More)
Preservation of fertility and optimizing health before pregnancy is becoming increasingly important in societies where childbirth often is postponed. Research shows that as women postpone childbirth they achieve higher levels of education and higher incomes. This leads to advantages for their children and for society. However, as women postpone childbearing(More)
OBJECTIVE The aim of this study was to evaluate if levels of gonadotropic and sex steroidal hormones influence the efficacy of mirabegron in the treatment of overactive bladder. METHODS We included 58 female participants who received treatment with mirabegron 50 mg once daily and provided a blood sample for hormone profiling before treatment was(More)
  • 1